University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
UCSF Is Top Public Recipient of NIH Research Funding for 6th Consecutive Year

UCSF Is Top Public Recipient of NIH Research Funding for 6th Consecutive Year

March 27, 2017

UC San Francisco was the top public recipient of biomedical research grants from the National Institutes of Health (NIH) for the sixth consecutive year in 2016, and the second-highest recipient among all public and private institutions nationwide, according to annual figures from the NIH.

2017 Faculty Research Lecture in Basic Science: Arturo Alvarez-Buylla

2017 Faculty Research Lecture in Basic Science: Arturo Alvarez-Buylla

March 20, 2017

Arturo Alvarez-Buylla, PhD, has been selected by his peers as the recipient of the 60th annual Faculty Research Lectureship (FRL) in Basic Science.

UCSF Precision Cancer Medicine Building Design Focuses on Patient Experience

UCSF Precision Cancer Medicine Building Design Focuses on Patient Experience

March 20, 2017

When the Precision Cancer Medicine Building (PCMB) opens in early 2019 in Mission Bay, it will serve as the new heart of outpatient cancer care at UCSF and will be a place in which patients and their loved ones can trust they are receiving ...
UCSF Scientists, Leaders Highlight Latest Advances at 2017 Precision Medicine World Conference

UCSF Scientists, Leaders Highlight Latest Advances at 2017 Precision Medicine World Conference

March 1, 2017

Scientists, clinicians and entrepreneurs shared the latest innovations and initiatives in the rapidly evolving movement to make health care more personal, predictive and preventive at the Precision Medicine World Conference (PMWC) in January.

Genetic 'Balance' May Influence Response to Cancer Treatment

Genetic 'Balance' May Influence Response to Cancer Treatment

February 27, 2017

Choosing among cancer treatments increasingly involves determining whether tumor cells harbor specific, mutated “oncogenes” that drive abnormal growth and that may also be especially vulnerable or resistant to particular drugs. But according to a new study led by UCSF researchers, in the case of the ...
Exploring Genomics' Gray Zone to Improve Cancer Treatment Options

Exploring Genomics' Gray Zone to Improve Cancer Treatment Options

February 15, 2017

Last year, UCSF launched the Molecular Oncology Initiative (MOI) to integrate molecular information found in most cancer types with the ever increasing number of therapeutics being developed in translational research and clinical practice.   The UCSF Molecular Tumor Board (MTB), a group of experts ...